Palisade Capital Management

Institutional Active United States
Last updated 2026-06-18
Portfolio
2
in our dataset
Rounds participated
2
Rounds led
0
Rounds' value
$32.7M
total disclosed, rounds participated
Stages
—

Portfolio · 2

Anchiano Therapeutics
Targeted Cancer Therapies Based on H19 Gene
1 round $4.7M committed Latest: 2016-10
Firefly Neuroscience
Measuring Brain Health
1 round $28.0M committed Latest: 2015-11

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences2

Q&A

What is Palisade Capital Management's primary sector focus for investments?
Palisade Capital Management primarily focuses on the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.
Can you name some notable portfolio companies of Palisade Capital Management?
Palisade Capital Management's portfolio includes Anchiano Therapeutics, which focuses on targeted cancer therapies.
Has Palisade Capital Management had any recent exits?
Yes, Palisade Capital Management had an exit in November 2021 when Firefly Neuroscience went public on NASDAQ.
What funding stages does Palisade Capital Management typically invest in?
Palisade Capital Management has participated in C Round and PIPE funding stages.
When did Palisade Capital Management make its most recent portfolio investments?
Palisade Capital Management made new portfolio investments in November 2015 and October 2016.